Press & News

ViewReleaseInStandardHtml

Three new shareholders in Boule Diagnostics

Svolder AB, Nordea Fonder and AB Grenspecialisten, none of whom previously held shares in Boule Diagnostics AB, have acquired 11.6 percent, 11.6 percent and 10.2 percent respectively of the shares in the company.

The shares have been sold by Siem Capital AB that, after 23 years as a shareholder, has divested its entire holding in Boule Diagnostics AB of 1,570,084 shares that represent 33.4 percent of the capital and voting rights in the company.

“We view this broadened ownership of the company as a positive move and our new and qualified investors as a stamp of quality,” says Ernst Westman, President and CEO, Boule Diagnostics AB.

The sale of the shares was arranged by Swedbank Corporate Finance.

For more information, please contact: Ernst Westman, President and CEO Boule Diagnostics AB, tel +46 708 60 88 63

About Boule Diagnostics AB (publ)
Boule Diagnostics AB (publ) is a company that develops, manufactures and markets instruments and consumables for haematology diagnostics. The company targets small and medium-sized hospitals, clinics and laboratories plus other diagnostics companies within the human and veterinary market of haematology diagnostics. The company is part of an international group with subsidiary companies in Sweden, USA and China. Boule Diagnostics shares have been listed on NASDAQ Stockholm since 2011. www.boule.se